Akoya Biosciences
Akoya, Singapore Consortium Collaborate to ID Markers of Response to Checkpoint Inhibitor Therapy
The project will use Akoya's PhenoCode Discovery IO60 Panel to look at matched pairs of immuno-oncology exceptional responders and hyper-progressors.
Akoya Biosciences, NeraCare Partner to Develop Melanoma Tests
The companies will develop tests for patient stratification and therapy selection for early melanoma using the PhenoImager HT platform and Immunoprint assay.
Agilent, Akoya to Commercialize Workflow Tools for Tissue Biomarker Analysis
The end-to-end workflow products are intended for biopharmaceutical companies developing companion diagnostics for precision cancer therapeutics.
Akoya Biosciences, Acrivon Therapeutics Partner to Develop CDx
The companies will codevelop, validate, and commercialize a companion diagnostic for Acrivon's targeted DNA damage response inhibitor therapy, ACR-368.
Akoya Biosciences, AstraZeneca Collaborate on Spatial Biomarker Profiling for Immuno-Oncology
The firms will study drug mechanisms of action, confirm the prevalence of targets, and discover predictive signatures for subsequent trial designs.